Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children
A Phase III, Observer-Blind, Randomized, Controlled Study of the Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Aged 12-17 Years in Indonesia
Sponsor: Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM
This PHASE3 trial investigates Vaccine Adverse Reaction and Vaccine Reaction and is currently completed. Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM leads this study, which shows 8 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jun 2025 — Present [monthly]
Completed PHASE3
Status: Unknown → Completed
-
May 2025 — Jun 2025 [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
May 2023 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE3
Phase: PHASE2_PHASE3 → PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Child Health Universitas Gadjah Mada (CCH-PRO UGM
- Cipto Mangunkusumo Hospital/Department of Child Health, Faculty of Medicine, University of Indonesia, Jakarta
- Faculty of Medicine, Andalas University
- PT Bio Farma
For direct contact, visit the study record on ClinicalTrials.gov .